Nexavar misses primary endpoint


Bayer and partner Onyx’s multi-tyrosine kinase and RAF-1-inhibitor sorafenib (Nexavar) may not significantly slow hepatocellular carcinoma (HCC) progression in responders (=25% tumor shrinkage or necrosis) to transarterial chemoembolisation (TACE), the firms said on the weekend at the meeting for the American Society of Clinical Oncology Gastrointestinal Cancers in Orlando. The drug missed the primary endpoint of significantly increasing time to progression in a phase III trial conducted with 456 patients in Japan and Korea. Median time to progression or recurrence was 5.4 months in the sorafenib arm, and 3.7 months in the placebo arm. Overall survival was similar in the two groups. The researchers concluded that further study evaluating the safety and efficacy of sorafenib in combination with TACE is warranted; it is also approved for the treatment of liver cancer without TACE (more...), and for the treatment of advanced kidney cancer. Additionally, researchers from France and Canada have reported that patients with advanced renal cell cancer (RCC) and treated with Nexavar® (sorafenib) showed muscle wastage. The details of this study have appeared in an early online publication in the Journal of Clinical Oncology. In April, the companies announced that sorafenib tosylate had failed in a phase III trial conducted as a first-line therapy in melanoma patients (more...).

Germany, FranceGermany


Martinsried/Paris - Sanofi has done some Christmas shopping in Munich and has licensed Scil Technology’s programme for the regenerative treatment of osteoarthritis and cartilage disorders. Under the agreement, Scil could reap up...



Monheim - It's nearly Christmas, and Bayer Crop Science gives out some presents. As the company announced, a $750 million settlement with U.S. rice farmers is now binding and can move forward. In summer the German firm had agreed...



Bonn – Germany’s federal government is prolonging one of its most successful measures to date for stimulating the establishment of high-tech companies – the High-Tech-Gründerfonds (HTGF). The HTGF was launched in 2005 with €272m...



Leverkusen – One short statement from the European Medicines Agency (EMA) means one giant step for German biotech company Biofrontera. The agency issued a favourable opinion on the firm’s marketing approval application for its...



While the European sovereign debt crisis keeps capital markets in a choke-hold, with potential negative effects on the financing situation in many industries – including biotech – there was encouraging news for drug-developing...



Heidelberg – There is still life in the European life science finance. EMBL Ventures has closed a €40m fund. The early stage investor and the venture capital arm of the European Molecular Biology Laboratory(EMBL) announced the...



Düsseldorf – BIO-Europe 2011 in Düsseldorf has again broken all previous records in terms of participants and company numbers. More than 3,000 representatives from 1,800 companies registered for Europe‘s largest partnering event....



Brussels/San Francisco – As the biggest biotech partnering event on the continent, BioEurope, draws to a close, the venture capital community sent ambivalent messages for life sciences. Dow Jones VentureSource, an analyst,...

Displaying results 11 to 20 out of 454

< Previous 11-20 Next >

© 2007-2014 BIOCOM

Product of the week



All Events

Current issue

All issues